GRI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GRI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the three months ended in Mar. 2024, GRI Bio received $5.50 Mil more from issuing new shares than it paid to buy back shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It spent $1.01 Mil on other financial activities. In all, GRI Bio earned $4.49 Mil on financial activities for the three months ended in Mar. 2024.
The historical data trend for GRI Bio's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRI Bio Annual Data | |||||||
Trend | Dec21 | Dec22 | Dec23 | ||||
Cash Flow from Financing | 0.60 | 1.01 | 10.80 |
GRI Bio Quarterly Data | ||||||||||
Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cash Flow from Financing | Get a 7-Day Free Trial | - | 6.92 | - | - | 4.49 |
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
GRI Bio's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Flow from Financing | (A: Dec. 2023 ) | ||||||||||
= | Issuance of Stock | + | Repurchase of Stock | + | Net Issuance of Debt | + | Net Issuance of Preferred Stock | + | Cash Flow for Dividends | + | Other Financing |
= | 12.25 | + | 0 | + | 1.25 | + | 0 | + | 0 | + | -2.703 |
= | 10.80 |
GRI Bio's Cash from Financing for the quarter that ended in Mar. 2024 is:
Cash Flow from Financing | (Q: Mar. 2024 ) | ||||||||||
= | Issuance of Stock | + | Repurchase of Stock | + | Net Issuance of Debt | + | Net Issuance of Preferred Stock | + | Cash Flow for Dividends | + | Other Financing |
= | 5.5 | + | 0 | + | 0 | + | 0 | + | 0 | + | -1.014 |
= | 4.49 |
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRI Bio (NAS:GRI) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
GRI Bio's issuance of stock for the three months ended in Mar. 2024 was $5.50 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
GRI Bio's repurchase of stock for the three months ended in Mar. 2024 was $0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
GRI Bio's net issuance of debt for the three months ended in Mar. 2024 was $0.00 Mil. GRI Bio received $0.00 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
GRI Bio's net issuance of preferred for the three months ended in Mar. 2024 was $0.00 Mil. GRI Bio paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
GRI Bio's cash flow for dividends for the three months ended in Mar. 2024 was $0.00 Mil. GRI Bio received $0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
GRI Bio's other financing for the three months ended in Mar. 2024 was $-1.01 Mil. GRI Bio spent $1.01 Mil on other financial activities.
Thank you for viewing the detailed overview of GRI Bio's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
David Leslie Szekeres | director | C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT, SUITE 210, SAN DIEGO CA 92121 |
Roelof Rongen | director | C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921 |
Camilla V Simpson | director | 20 ELAINE AVE., MILL VALLEY CA 94941 |
Albert Agro | officer: Chief Medical Officer | 828 RICHMOND STREET WEST, TORONTO A6 M6J 1C9 |
Walter Marc Hertz | director, 10 percent owner, officer: Chief Executive Officer | 2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037 |
Vipin Chaturvedi | officer: Chief Scientific Officer | 2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037 |
Meenu Chhabra | director | C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103 |
Joseph E Payne | director | 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Leanne M. Kelly | officer: Chief Financial Officer | C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH STREET, SUITE 300, PHILADELPHIA PA 19103 |
Marella Thorell | director | 1226 CHARTER LANE, AMBLER PA 19002 |
Arcturus Therapeutics Holdings Inc. | 10 percent owner | 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121 |
Penny Toren | officer: SVP, Regul Affairs & Prog Mgmt | C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103 |
Ofir Levi | director | C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103 |
Richard Ammer | director, 10 percent owner | C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103 |
Pharma Gmbh Salmon | 10 percent owner | SANKT-JACOBS-STRASSE 90, CH-9002, BASEL V8 4052 |
From GuruFocus
By sperokesalga sperokesalga • 05-22-2023
By sperokesalga sperokesalga • 06-15-2023
By Marketwired • 07-05-2023
By Marketwired • 07-24-2023
By Marketwired • 10-05-2023
By Marketwired • 06-27-2023
By Marketwired • 09-06-2023
By ACCESSWIRE • 08-25-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.